

**WHO GUIDELINE
ON MASS DRUG
ADMINISTRATION OF
AZITHROMYCIN TO
CHILDREN UNDER
FIVE YEARS OF AGE
TO PROMOTE
CHILD SURVIVAL**



World Health
Organization

**WHO GUIDELINE
ON MASS DRUG
ADMINISTRATION OF
AZITHROMYCIN TO
CHILDREN UNDER
FIVE YEARS OF AGE
TO PROMOTE
CHILD SURVIVAL**



**World Health
Organization**

WHO guideline on mass drug administration of azithromycin to children under five years of age to promote child survival

ISBN 978-92-4-000958-5 (electronic version)

ISBN 978-92-4-000959-2 (print version)

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. WHO guideline on mass drug administration of azithromycin to children under five years of age to promote child survival. Geneva: World Health Organization; 2020. Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Photo credit (front cover): Mark Nieuwenhof

Cover design and layout: Jean- Claude Fattier

CONTENTS

Acknowledgements	v
Abbreviations	vi
Executive summary	vii
Guideline purpose and scope	vii
Guideline development methodology	vii
Available evidence	viii
Recommendations	viii
Remarks	ix
Rationale	x
Introduction	1
Background	1
Purpose and scope	2
Key questions (PICO)	2
Summaries of Evidence	4
Overview of evidence retrieved, assessment and synthesis	4
Review 1: Effect of mass drug administration of azithromycin on mortality and morbidity	4
Review 2: Effect of mass drug administration of azithromycin on antimicrobial resistance	8
Review 3: Serious adverse effects and dose for mass drug administration of azithromycin	12
Recommendations	16
Recommendations	16
Remarks	16
Rationale for recommendations	17
Research gaps	20
Guideline Development Process	21
Guideline development group	21
Quality of evidence grading	21
Managing conflicts of interest	22
Decision-making process	22
Peer review groups	23

Dissemination and Plan for updating -----	24
References -----	25
Annex 1	
Effect of mass drug administration of azithromycin on mortality and morbidity – PRISMA flowchart and GRADE tables -----	26
Annex 2	
Effect of mass drug administration of Azithromycin on antimicrobial resistance – PRISMA flowchart -----	32
Annex 3	
Serious adverse effects of mass drug administration of Azithromycin – PRISMA flowchart-----	33
Annex 4 -----	34
Acknowledgements-----	34
Guideline development group -----	34
External peer reviewers -----	35
Lead scientists who conducted systematic reviews-----	36
WHO Guideline Steering Group -----	36
Funding -----	36
Annex 5 -----	37
Expert group consultations 2018-----	37

ACKNOWLEDGEMENTS

The Department for Maternal, Newborn, Child, Adolescent Health and Aging of the World Health Organization gratefully acknowledges the contributions that many individuals and organizations made to the development of these guidelines.

The technical input of the members of the Guideline development group involved in developing the recommendations, especially the chairs of the two meetings concerning this guideline: Prof. MK Bhan and Prof. Robert Black, is acknowledged. Feedback from external peer reviewers of this guideline is also recognized.

WHO is also grateful to the academic groups at the All India Institute of Medical Sciences (Dr. Mari Jeeva Sankar), New Delhi, the University of Nottingham (Prof. Imti Choonara) and St. George's University hospital, London (Dr. Julia Bielecki and Prof. Mike Sharland) for their detailed review of literature and development of the systematic reviews that were used to inform this guideline.

The Guidelines Review Committee and the Science Division (Norms and Standards) are acknowledged for their technical support throughout the process.

This guideline was coordinated by Department of Maternal, Newborn, Child, Adolescent health and Aging (Dr. Jonathon Simon, Dr Ayesha De Costa and Dr Rajiv Bahl), in partnership with the Departments of Immunization, Vaccines and Biologicals (Dr. Adwoa Bentsi-Enchill), Essential Medicines and Health Products (Dr. Nicola Magrini), Antimicrobial Resistance (Dr. Carmem Pessoa da Silva), Neglected Tropical Diseases (Dr. Anthony Solomon), and the Global Malaria Programme (Dr. David Schellenberg).

USAID provided financial support for this work. Donors do not fund specific guidelines and do not participate in any decision related to the guideline development process, including the composition of research questions, membership of the guideline development groups, conduct and interpretation of systematic reviews, or formulation of recommendations.

ABBREVIATIONS

ADR	Adverse drug reaction
AE	Adverse event
AMR	Antimicrobial resistance
ARI	Acute respiratory infection
AZM	Azithromycin
CI	Confidence interval
DECIDE	Developing and Evaluating Communication Strategies to support Informed Decisions and Practice based on Evidence
ECG	Electrocardiogram
EML	Essential Medicines List (WHO)
FDR	Food and Drug Administration (US)
GDG	Guideline Development Group (independent of WHO)
GRADE	Grading of Recommendations, Assessment, Development and Evaluation
GRC	Guidelines Review Committee (WHO)
GSG	Guideline Steering Group (WHO)
IHPS	Infantile hypertrophic pyloric stenosis
IMR	Infant mortality rate
IRR	Incidence rate ratio
LMIC	Low- and middle-income country
MCA	Maternal, Child and Adolescent health
MDA-azithromycin	Mass drug administration of azithromycin
MORDOR	Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance
OR	Odds ratio
PRC	Peer Review Group

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24420

